Therapeutic vaccination with Tat restores immune homeostasis, promotes proviral DNA decay and induces cross clade neutralizing antibodies in patients on HAART: Results from phase II clinical trials in Italy and South Afr
memory subsets, independently from CD4 nadir and particularly in the most immunocompromised patients. Remarkably, proviral DNA load progressively decreased in vaccines. Reduction correlated with anti-Tat Ab titers and…

